Gensight Biologics SA Asset Resilience Ratio

Latest as of June 2022: 59.58%

Gensight Biologics SA asset resilience ratio. Gensight Biologics SA (SIGHT) has an Asset Resilience Ratio of 59.58% as of June 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Gensight Biologics SA to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€24.15 Million
≈ $28.23 Million USD Cash + Short-term Investments

Total Assets

€40.52 Million
≈ $47.38 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Gensight Biologics SA (2014–2021)

Asset resilience ratio of Gensight Biologics SA from 2014 to 2021. This chart shows how Gensight Biologics SA's Asset Resilience Ratio has changed over time. Read total liabilities of Gensight Biologics SA for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Gensight Biologics SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SIGHT current and non-current assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €24.15 Million 59.58%
Short-term Investments €0.00 0%
Total Liquid Assets €24.15 Million 59.58%

Asset Resilience Insights

  • Very High Liquidity: Gensight Biologics SA maintains exceptional liquid asset reserves at 59.58% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Gensight Biologics SA Industry Peers by Asset Resilience Ratio

Compare Gensight Biologics SA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
Biotechnology 35.16%
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294
Biotechnology 23.15%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Achieve Life Sciences Inc
F:SP4P
Biotechnology 3.60%

Gensight Biologics SA Asset Resilience Ratio by Year (2014–2021)

Gensight Biologics SA asset resilience ratio by year from 2014 to 2021. The table below shows the annual Asset Resilience Ratio data for Gensight Biologics SA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2021-12-31 78.18% €44.29 Million
≈ $51.78 Million
€56.65 Million
≈ $66.23 Million
-1.93pp
2020-12-31 80.11% €37.94 Million
≈ $44.36 Million
€47.36 Million
≈ $55.37 Million
+20.85pp
2019-12-31 59.26% €19.25 Million
≈ $22.51 Million
€32.48 Million
≈ $37.98 Million
-11.70pp
2018-12-31 70.96% €26.24 Million
≈ $30.68 Million
€36.98 Million
≈ $43.23 Million
-18.17pp
2017-12-31 89.13% €55.45 Million
≈ $64.82 Million
€62.21 Million
≈ $72.73 Million
-2.01pp
2016-12-31 91.14% €53.98 Million
≈ $63.11 Million
€59.23 Million
≈ $69.25 Million
+81.68pp
2014-12-31 9.46% €1.40 Million
≈ $1.64 Million
€14.82 Million
≈ $17.32 Million
--
pp = percentage points

About Gensight Biologics SA

PA:SIGHT France Biotechnology
Market Cap
$20.04 Million
€17.14 Million EUR
Market Cap Rank
#24959 Global
#400 in France
Share Price
€0.07
Change (1 day)
-5.31%
52-Week Range
€0.07 - €0.14
All Time High
€9.58
About

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV… Read more